NEWARK, Calif., Aug. 1, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will release second quarter fiscal year 2013 financial results after the market closes on Wednesday, August 7, 2013. The Company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm Pacific time to discuss its results.
Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
Depomed, Inc. is a specialty pharmaceutical company with four approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Zipsor ® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug for the management of breakthrough pain in cancer patients
CONTACT: August J. Moretti Depomed, Inc. 650-462-5900 email@example.com
SOURCE Depomed, Inc.